Viral Infection And TGFbeta Impair Glucocorticoid Activity In Epithelial Cells
Funder
National Health and Medical Research Council
Funding Amount
$617,699.00
Summary
Chronic inflammatory lung diseases like asthma and smokers lung are treated with combinations of anti-inflammatory drugs. Powerful anti-inflammatory types of steroid drugs are used in more severe disease. Even these powerful drugs are sometimes not effective enough. Our work is developing an understanding of how inflammation limits the anti-inflammatory effects of steroids and we are devising ways to overcome this with new drugs. We aim to improve treatment of chronic inflammatory diseases, espe ....Chronic inflammatory lung diseases like asthma and smokers lung are treated with combinations of anti-inflammatory drugs. Powerful anti-inflammatory types of steroid drugs are used in more severe disease. Even these powerful drugs are sometimes not effective enough. Our work is developing an understanding of how inflammation limits the anti-inflammatory effects of steroids and we are devising ways to overcome this with new drugs. We aim to improve treatment of chronic inflammatory diseases, especially those affecting the lung.Read moreRead less
Viral Infection And Transforming Growth Factor-beta Impair Glucocorticoid Activity In Epithelial Cells
Funder
National Health and Medical Research Council
Funding Amount
$318,299.00
Summary
Anti-inflammatory types of steroid drugs are commonly used in chronic lung disease including asthma and chronic obstructive pulmonary disease. However, a significant number of sufferers show resistance to the steroid therapy. Our study is developing an understanding of how inflammation limits the anti-inflammatory effects of steroids and we are identifying novel therapeutic targets to improve the effectiveness of treatment of chronic disease.
This proposal utilises forefront technologies to identify and characterise fundamental biological processes influenced by toxic free radicals that are triggered by viruses such as the flu and HIV. The approach is a synergistic collaboration between researchers with unique and complementary expertise across disciplines and across Australian and Irish universities to ultimately identify future drugs to treat viral disease.